Vanucizumab
Vanucizumab is a first-in-class, bispecific IgG1-like monoclonal antibody that simultaneously blocks VEGF-A and angiopoietin-2 (Ang-2) from interacting with their receptors. Vanucizumab has antiangiogenic and anticancer effects[1].
Product Specifications
CAS Number
1448221-05-3
Product Name Alternative
Anti-Human VEGFA Recombinant Antibody; RO5520985
UNSPSC
12352203
Target
Tie; VEGFR
Type
Inhibitory Antibodies
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/vanucizumab.html
Purity
95.12
Solubility
10 mM in DMSO
Smiles
[Vanucizumab]
Molecular Weight
(146.89 kDa)
References & Citations
[1]Manuel Hidalgo, et al. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors. Clin Cancer Res. 2018 Apr 1;24 (7) :1536-1545.|[2]Wolfgang Schaefer, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A. 2011 Jul 5;108 (27) :11187-92.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![PE Anti-Mouse CD86 Antibody[GL-1]](https://cdn.genprice.uk/products/763/68dd14a2061270361e7d0ecf/imageurl/e-ab-f0994d.webp)
